Back to top

Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated

In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals, with a price target of $43....

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

EyePoint, Inc. (EYPT)